RxDoctor Payments Data

Nikki Hughes, MD

Family Medicine · Buford, GANPI 1053490938

Payments from drug & device makers

$11,704in general payments, 2019–2025

Across 747 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$764
  • Takeda Pharmaceuticals U.S.A., Inc.$749
  • AstraZeneca$731
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$11,64499%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,704 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$52,055
Medicare patients
116
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$122,914
OzempicSemaglutide119$122,273
JardianceEmpagliflozin85$70,719
EliquisApixaban59$54,734
RybelsusSemaglutide27$42,395
FarxigaDapagliflozin Propanediol43$33,390
ProliaDenosumab12$20,885
Repatha SureclickEvolocumab20$18,670
MyrbetriqMirabegron26$16,592
VascepaIcosapent Ethyl22$14,105
KerendiaFinerenone18$12,256
EntrestoSacubitril/Valsartan15$9,293
Tresiba Flextouch U-200Insulin Degludec15$8,022
SynthroidLevothyroxine Sodium36$2,591
Rosuvastatin Calcium208$1,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,349$164,667146 claims
Lilly USA, LLCMounjaro$1,002$122,91498 claims
Boehringer IngelheimJardiance$764$70,71985 claims
PfizerEliquis$257$54,73459 claims
AstraZenecaFarxiga$731$33,39043 claims
AmgenProlia$674$20,88512 claims
Astellas Pharma US IncMyrbetriq$87$16,59226 claims
BayerKerendia$337$12,25618 claims
NovartisEntresto$125$9,29315 claims
AbbVieSynthroid$1,451$2,59136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →